证券研究报告 公司研究 [Table_ReportType] 公司点评报告 [Table_StockAndRank] 新产业(300832) 投资评级 上次评级 [Table_Author] 唐爱金 医药行业首席分析师 执业编号：S1500523080002 邮 箱：tangaijin@cindasc.com 贺鑫 医药行业联席首席分析师 执业编号：S1500524120003 邮 箱：hexin1@cindasc.com 曹佳琳 医药行业分析师 执业编号：S1500523080011 邮 箱：caojialin@cindasc.com 相关研究 [Table_OtherReport] 大型机占比持续提升，收入展现增长 韧性 海外业务稳健增长，大型机装机持续 推进 大型机占比持续提升，助力业绩稳健 增长 信达证券股份有限公司 CINDA SECURITIES CO.,LTD 北京市西城区宣武门西大街甲127号金隅大厦B 座 邮编：100031 [Table_Title] 海外业务稳步增长，国内市场短期承压 [Table_ReportDate] 2025 年 09 月 03 日 [Table_S 事件：公司发布 ...

Summary of Key Points Core Viewpoint The report outlines the fundraising activities and the status of the funds raised by Seirus Medical Technology Group Co., Ltd. It highlights the termination of certain fundraising projects and the reallocation of remaining funds to enhance liquidity and operational efficiency in response to changing market conditions. Fundraising Overview - In 2018, the company raised approximately RMB 625.96 million through a non-public offering of A-shares, with a net amount of RMB 607.61 million after expenses [1][2] - As of June 30, 2025, the remaining balance of the non-public fundraising was RMB 8.99 million, including interest [2] Fund Usage and Management - By June 30, 2025, the company had utilized RMB 202.78 million of the funds raised from the 2020 convertible bond issuance, leaving a balance of RMB 333.89 million [4] - The company has established dedicated bank accounts for the management of the raised funds, ensuring compliance with regulatory requirements [7][18] Project Termination and Fund Reallocation - The company decided to terminate the "Expansion of Medical Testing Integrated Marketing and Service Business Scale Project" due to significant changes in the market environment and profitability concerns, reallocating the remaining RMB 172.54 million to enhance liquidity [28][29] - The decision was made after thorough evaluations and was approved in board meetings held in June 2025 [28] Financial Management Practices - The company has implemented a structured approach to manage the raised funds, including regular audits and checks by the finance department to ensure proper usage [7][24] - The company has also utilized idle funds temporarily to supplement working capital, with repayments made as scheduled [24][31] Regulatory Compliance - The company has adhered to various regulations regarding fundraising and fund management, including the establishment of tripartite agreements with banks and sponsors to ensure proper oversight [7][18][22]

深圳市新产业生物医学工程股份有限公司 投资者关系活动记录表 证券代码：300832 证券简称：新产业 编号：2025-008 深圳市新产业生物医学工程股份有限公司 投资者关系活动记录表 | | □特定对象调研 □分析师会议 | | | | --- | --- | --- | --- | | | □媒体采访 □业绩说明会 | | | | 投资者关系 活动类别 | □路演活动 | □新闻发布会 | | | | ☑现场参观 | | | | | ☑其他 线上交流、摩根士丹利策略会、华福证券策略会 | | | | 参与单位名 | | | | | 称及人员姓 | 共计 家机构，218 名参会人员，详见附件《与会机构名单》 166 | | | | 名 | | | | | | 年 月 月 日 2025 8 26 日-8 29 | | | | 地点 | 深圳市坪山区坑梓街道金沙社区锦绣东路 号新产业生物大厦 23 | | | | | 等； | | | | 上市公司接 | 副总经理兼董事会秘书 张蕾 | | | | 待人员姓名 | | | | | | 投资者关系负责人 吕宇宁 | | | | | 公司于 8 月 26 日发布了《 ...